Supplementary Figures from Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figures S1: Activity of combined treatment with venetoclax and GDC-0980 in human AML cells. Supplementary Figures S1: Synergistic interaction between venetoclax and GDC-0980 using median dose effect analysis. Supplementary Figures S3: Effects of venetoclax/GDC-0980 on PI3K/AKT/mTOR pathway activity and BCL-2 members expression. Supplementary Figure S4: Mutation analysis of primary AML specimens using targeted next-generation sequencing. Supplementary Figure S5. Combined treatment with venetoclax/GDC-0980 or taselisib exhibits potent in vivo anti-AML activity without significant toxicity Supplementary Figure S6. BIM is not required for BAX activation by venetoclax or venetoclax/GDC-0980, and Mcl-1 downregulation plays a significant functional role in venetoclax/GDC-0980 lethality. Supplementary Figure S7. Mitochondrial BAX translocation in venetoclax-resistant MV4-11 cells following combined treatment
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362422804